Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 59

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 59
---
 such distributor owes us on a timely basis, or at all, it could
negatively affect our business and results of operations. In addition, if one of our significant wholesale distributors becomes insolvent
or otherwise unable to continue its commercial relationship with us in its present form, it could significantly disrupt our business
and adversely affect our product sales, our business and results of operations unless suitable alternatives are timely found or lost
sales are absorbed by another distributor.

 35 

If we are unable to protect our proprietary
rights, we may not be able to prevent others from using our intellectual property, which may reduce the competitiveness and value of
the related assets.

Our success will depend in part
on our ability to obtain and maintain patent protection for our formulations and technologies and to prevent third parties from infringing
upon our proprietary rights. We must also operate without infringing upon patents and proprietary rights of others, including by obtaining
appropriate licenses to patents or other proprietary rights held by third parties, if necessary. The primary means by which we will be
able to protect our formulations and technologies from unauthorized use by third parties is to obtain valid and enforceable patents that
cover them. However, the applications we have filed or may file in the future may never yield patents that protect our inventions and
intellectual property assets. Failure to obtain patents that sufficiently cover our formulations and technologies would limit our protection
against other compounding pharmacies and outsourcing facilities, generic drug manufacturers, pharmaceutical companies and other parties
who may seek to copy our products, produce products substantially similar to ours or use technologies substantially similar to those
we own. We have made, and expect to continue to make, significant investments in certain of our proprietary formulations prior to the
grant of any patents covering these formulations, and we may not receive a sufficient return on these investments if patent coverage
or other appropriate intellectual property protection is not obtained and their competitiveness and value decreases.

The patent and intellectual property
positions of pharmacies and pharmaceutical companies, including ours, are uncertain and involve complex legal and factual questions.
There is no guarantee that we have developed or obtained or will in the future develop or obtain the rights to products or processes
that are patentable, that patents will issue from any pending applications or that claims allowed will be sufficient to protect the technology
we have developed or may in the future develop or to which we have acquired or may in the future acquire development rights. In addition,
we cannot be certain that patents issued to us will not be challenged, invalidated, infringed or circumvented